# Leadership, Planning and Evaluation

> **NIH NIH P30** · WASHINGTON UNIVERSITY · 2021 · $388,751

## Abstract

LEADERSHIP, PLANNING AND EVALUATION: PROJECT SUMMARY
Siteman Cancer Center (SCC) Director, Timothy Eberlein, sets the vision for SCC, creates policy, and builds
consensus prior to implementation of key decisions. He has broad authority and is the ultimate arbiter for all
scientific and administrative matters, with Senior Leadership (SL) providing critical support and advice. The SL,
chaired by the Director, is SCC’s central decision-making and internal advisory body. SL vets all SCC strategies,
priorities, policies, and budgetary decisions. SL is structured to facilitate research productivity; promote cross-
program and cross-discipline collaboration; and, leverage institutional strengths to increase SCC’s impact in the
region, nation, and field of cancer research. SL’s collective expertise and institutional influence help to foster and
further SCC’s vision and mission, while integrating research efforts and promoting transdisciplinary and
translational research relevant to the catchment area.
 Continuous evaluation of SCC progress and planning for future initiatives is accomplished with the direction
of specialized external and internal advisory committees, under the oversight of the SCC Director and SL. The
External Advisory Committee (EAC) plays an essential role, shaping SCC’s direction through an intensive annual
review and report on strengths and key opportunities for improvement. EAC reviews SCC’s leadership structure,
research programs, education and training initiatives, administration/operations, and overall scientific impact in
the catchment area. Other important committees that include members external to Washington University (WU)
are the Community Advisory Board and Patient and Family Advisory Council.
SCC relies on several internal advisory committees and working groups to fulfill key functions:
  Guide strategic planning – Joint Office of Strategic Planning, SCC Strategic Plan Steering Committee;
  Review SCC’s clinical trial portfolio, accruals, and activation – Clinical Research Committee;
  Set research program priorities – Program-Specific Leadership Committees;
  Evaluate shared resource performance, needs, and relevance to SCC member research – Shared
 Resource Review;
  Conduct peer-review of funding requests and make recommendations for funding – Siteman Investment
 Program Research Development Award mechanism; and
  Review new member applications and eligibility of existing members – SCC Membership Committee.
SCC’s access to institutional leaders reflects the Center’s prominence and priority within its parent institutions,
WU School of Medicine (WUSM) and Barnes-Jewish Hospital (BJH). The elevated stature of SCC within WU
and BJH affords the Director unique access to the WU Chancellor and BJC HealthCare CEO (biannual meetings)
and the BJH President and WUSM Dean (monthly meetings).

## Key facts

- **NIH application ID:** 10217029
- **Project number:** 5P30CA091842-20
- **Recipient organization:** WASHINGTON UNIVERSITY
- **Principal Investigator:** TIMOTHY J. EBERLEIN
- **Activity code:** P30 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $388,751
- **Award type:** 5
- **Project period:** 2001-08-02 → 2025-06-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10217029

## Citation

> US National Institutes of Health, RePORTER application 10217029, Leadership, Planning and Evaluation (5P30CA091842-20). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10217029. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*